ADAM9 and cancer: These data indicate the potential for suppression of leukotriene C4 and leukotriene D4 with leukotriene receptor antagonists to enhance the elimination of cancer cells by NK cells through ADAM9 inhibition, and subsequent inhibition of MICA shedding, potentially upregulating MICA expression.